While the exact mechanism for reduced levels of carnitine compounds in the CSF of patients with TP53-mutant GBM remains to be elucidated, impaired TP53 regulation of CPT1C expression in TP53-mutant GBM may be a contributing factor. This evidence concerns the gene TP53 and glioblastoma.